[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543740":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":20,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Patients with TED will be recruited in the study.\n\nInterventions:\n\nDiagnostic Test: 18F-AlF-FAPI PET\u002FCT and 99mTc-DTPA SPECT\u002FCT.",[13],"Diagnostic Test: 18F-AlF-FAPI PET\u002FCT, 99mTc-DTPA SPECT\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-AlF-FAPI PET\u002FCT, 99mTc-DTPA SPECT\u002FCT","Patients underwent 18F-AlF-FAPI PET\u002FCT and 99mTc-DTPA SPECT\u002FCT scans within 10 days.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Hui Li, Dr.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","86-13121136769","huilee1990@163.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Lingge Suo, Dr.","86-010-82264935","suolingge_1019@126.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Dept. of Nuclear Medicine, Peking University Third Hospital","RECRUITING","Beijing","Beijing Municipality","100191","China",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49,50,51],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100543740",false,"NCT06359795","Exploring the Value of 18F-AlF-FAPI PET\u002FCT in Assessing the Activity of Thyroid Eye Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Patients diagnosed with TED;\n3. Complete understanding and voluntary participation in this study, with the signing of an informed consent form.\n\nExclusion Criteria:\n\n1. Severe liver or kidney dysfunction;\n2. Inability to maintain a supine position for 5 minutes to cooperate with the examination;\n3. Suffering from claustrophobia or other psychiatric disorders;\n4. Patients planning pregnancy or in the prenatal or lactation period;\n5. Other conditions deemed unsuitable for participation in the trial by the investigator.",true,"ALL","18 Years","80 Years",{"count":64,"type":65},50,"ESTIMATED","INTERVENTIONAL",[68],"NA","FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET\u002FCT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET\u002FCT may be superior to 99mTc-DTPA SPECT\u002FCT for the diagnosis, therapy response assessment, and follow-up of TED.",[71],"Thyroid Eye Disease","2024-04-07",{"date":74,"type":75},"2024-04-11","ACTUAL",{"date":77,"type":75},"2023-12-15",{"date":79,"type":65},"2027-12-31",{"name":5,"class":6},1]